Article thumbnail

Osteopenia and osteoporosis in people living with HIV: multiprofessional approach

By Ana Lucia Lei Munhoz Lima, Priscila Rosalba D de Oliveira, Perola Grimberg Plapler, Flora Maria D Andrea Marcolino, Eduardo de Souza Meirelles, André Sugawara, Riccardo Gomes Gobbi, Alexandre Leme Godoy dos Santos and Gilberto Luis Camanho

Abstract

Increasing bone mineralization abnormalities observed among people living with HIV (PLWHIV) result from various factors relating to the host, the virus, and the antiretrovirals used. Today, HIV infection is considered to be a risk factor for bone mineralization disorders. The test most recommended for diagnosing osteoporosis is measurement of bone mineral density by means of dual energy X-ray absorptiometry at two sites. Osteoporosis treatment has the aims of bone mass improvement and fracture control. A combination of calcium and vitamin D supplementation may reduce the risk of fractures. Antiresorptive drugs act by blocking osteoclastic activity and reducing bone remodeling. On the other hand, bone-forming drugs stimulate osteoblastogenesis, thereby stimulating the formation of bone matrix. Mixed-action medications are those that are capable of both stimulating bone formation and inhibiting reabsorption. Antiresorptive drugs form the group of medications with the greatest quantity of scientific evidence confirming their efficacy in osteoporosis treatment. Physical activity is a health promotion strategy for the general population, but only preliminary data on its real value and benefit among PLWHIV are available, especially in relation to osteoporosis

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3257973
Provided by: PubMed Central

Suggested articles

Citations

  1. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.
  2. Abordagem física para prevenção e tratamento de osteoporose.
  3. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy.
  4. AIDS – the first 20 years.
  5. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV .
  6. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.
  7. (2011). Available from: http://www.niams.nih.gov/Health_Info/Bone/ Bone_Health/Nutrition/default.asp. Accessed
  8. (2001). Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures. Osteoporosis Int.
  9. BMD is reduced in HIV-infected men irrespective of treatment.
  10. (2006). Bone disease and HIV Infection. Clin Infect Dis.
  11. (2010). Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis.
  12. Bone metabolism in children with human immunodeficiency virus infection receiving highly active anti-retroviral therapy including a protease inhibitor.
  13. (2001). Bone mineral density (BMD) in HIV1-infected patients. In:
  14. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.
  15. Calcio e outros minerais. In:
  16. (2003). Cardiovascular risk factors in HIV-infected patients. J Acquir Immune Defic Syndr.
  17. Characteristics of HIV-infected men with low serum testosterone levels.
  18. (2002). Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int.
  19. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.
  20. (2001). Decreases in total body bone mineral content progress with age in HIV-infected children. In:
  21. Dietary reference intakes: applications in dietary assessment.
  22. (1985). Digestive absorption of calcium phosphates in man. Presse Med.
  23. (2006). Efeito do treinamento resistido sobre a osteoporose após a menopausa: estudo de atualização/Effect of resistance training on postmenopausal osteoporosis: update. Rev Bras Epidemiol.
  24. Effect of exercise and strength training on cardiovascular status in HIV-infected patients receiving highly active antiretroviral therapy.
  25. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis.
  26. (2000). Epidemiologia da osteoporose e fraturas In: Szejnfeld V . Osteoporose: Diagnóstico e Tratamento. São Paulo: Sarvier;
  27. (2003). Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the
  28. (2008). Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis.
  29. High prevalence of reduced bone mineral density in primary HIV-1-infected men.
  30. (2010). HIV and bone loss. Curr Osteoporos Rep.
  31. (2005). HIV-1 Vpr enhances production of receptor of actived NF-KappaB ligant (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol.
  32. Impact of HAART on causes of death of persons with late-stage AIDS.
  33. (2007). Interventions for the treatment of decreased bone mineral density associated with HIV infection. Cochrane Database Syst Rev.
  34. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children.
  35. Low body weight mediates the relationship between HIV infection and low bone mineral density: a metaanalysis.
  36. Mechanisms of action of biphosphonates: similarities and differences and their potential influence on clinical efficacy.
  37. Metabolic bone disease in HIV infection.
  38. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture.
  39. (2011). National Academy of Sciences. Dietary Reference Intakes for Calcium and Vitamin D,
  40. (2003). Organization. AIDS Epidemic Update:
  41. Osteoarticular complications related to HIV infection and highly active antiretroviral therapy.
  42. (2002). Osteopenia and human immunodeficiency virus. Joint Bone Spine.
  43. Osteopenia in HIV infected men: association with asyntomatic lactic academia and lower weight pre antiretroviral therapy.
  44. (2000). Osteopenia in HIV infection.
  45. (2004). Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporosis Int.
  46. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infections who were receiving hightly active antiretroviral therapy. Clin Infect Dis.
  47. Prospective study of bone mineral density changes in aging men with or at risk for HIV infection.
  48. Reduced bone density in HIV-infected women.
  49. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health initiative randomized controlled trial.
  50. Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
  51. Severe deficiency of 1.25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis.
  52. Strontium ranelate may cause alopecia.
  53. The importance of diet and physical activity in the treatment of conditions managed in general practice.
  54. The use of PTH in the treatment of osteoporosis.
  55. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada.
  56. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.